Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for HIV-associated (AIDS-related) lymphomas, drawn from the whole corpus: 2 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Primary effusion lymphoma and multicentric Castleman disease respond poorly to chemotherapy; pomalidomide, anti-IL-6 and HHV-8-directed approaches are in AMC trials.
Plasmablastic lymphoma lacks CD20 and relapses early; bortezomib and daratumumab combinations are being tested.
Nothing recorded yet.
Also on OnCo: Treatment journeys · Survivorship planner.
CNS lymphoma at low CD4 counts remains hard to cure; high-dose methotrexate with antiretroviral therapy is now the approach rather than radiotherapy alone.
Most HIV-associated lymphoma now occurs in sub-Saharan Africa with limited access to rituximab, pathology and supportive care; global oncology programmes are the response.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Financial help · Coverage by country · HTA decisions.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 11 changes by month →When this page itself was last checked or edited.
Case series and the AMC-sponsored study show safety; trial eligibility broadened.
Kaposi sarcoma (AIDS-related after ART failure; HIV-negative)
Outcomes comparable to HIV-negative controls.
One-year overall survival 87.
R-CHOP or dose-adjusted EPOCH-R at full dose with concurrent antiretroviral therapy (avoiding boosted protease inhibitors or cobicistat where possible), G-CSF support and opportunistic-infection prophylaxis; CNS prophylaxis by risk. (NCCN Category 2A)